Wojciech Krzyzanski
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Wojciech Krzyzanski has a total of 104 co-authors. Here are the top co-authors by number of shared publications:
Xiaoyu Yan
School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong
7 shared publications- Juan Jose Perez Ruixo
Johnson & Johnson Madrid Spain
5 shared publications - Paweł Wiczling
Department of Biopharmaceutics and Pharmacodynamics, Medical University of Gdañsk, Gdañsk, Poland
5 shared publications An Vermeulen
Janssen R&D Division of Janssen Pharmaceutica NV Beerse Belgium
4 shared publications- Philip J. Lowe
Novartis Pharma AG, Basel, Switzerland
4 shared publications - Karel Allegaert
Department of Development and Regeneration, KU Leuven, Leuven, Belgium
3 shared publications
Latest Publications
- Open Access
- 6 July 2026
- Published by Springer Nature in Journal of Pharmacokinetics and Pharmacodynamics
- Vol. 53 (5) , 36
Cohort population analysis of sparse data: Dexamethasone pharmacokinetics in mother and fetus based on blood sampling at birth
We introduced an estimation technique for mixed effect models that stems from non-parametric methods of estimation and fully parametric mixture models with cohort population as a central concept. The cohort population partitions data variability into between-cohorts and residual variabilities. This permits maximum likelihood estimates of model parameters from sparse data such as one observation per subject. Our second objective was to test robustness of cohort population estimation technique using previously published pharmacokinetic data on dexamethasone in parturient women. We performed two studies. In Study I we generated 100 dense and sparse datasets and refitted the data to quantify the difference between parameter estimates obtained by the cohort population model and the standard estimation methods. In Study II we evaluated robustness of cohort population model using dexamethasone maternal and fetal plasma concentrations obtained at childbirth after intramuscular injection of two 8 mg antenatal doses of dexamethasone phosphate in pregnant women. We implemented in NONMEM 7.6 the 3-cohort population as a mixture population model and applied first order conditional estimation, stochastic approximation, and importance sampling methods for parameter estimation. We showed that cohort estimation can quantify the variability in (log)normal populations where between-cohort variability is a substitute for between-subject variability. The cohort estimates of structural model parameters were equally accurate than the standard estimates and the accuracy and precision of estimates of inter-individual variability parameters for sparse data were better than for the standard maximum likelihood methods. Finally, we showed that the cohort population estimates provided meaningful quantification of one compartment model parameters for dexamethasone in parturient women where data were limited only to one blood sample per subject drawn after childbirth.
- 6 July 2026
- Published by Springer Nature in Journal of Pharmacokinetics and Pharmacodynamics
- Vol. 53 (5) , 36
Open AccessCohort population analysis of sparse data: Dexamethasone pharmacokinetics in mother and fetus based on blood sampling at birth
We introduced an estimation technique for mixed effect models that stems from non-parametric methods of estimation and fully parametric mixture models with cohort population as a central concept. The cohort population partitions data variability into between-cohorts and residual variabilities. This permits maximum likelihood estimates of model parameters from sparse data such as one observation per subject. Our second objective was to test robustness of cohort population estimation technique using previously published pharmacokinetic data on dexamethasone in parturient women. We performed two studies. In Study I we generated 100 dense and sparse datasets and refitted the data to quantify the difference between parameter estimates obtained by the cohort population model and the standard estimation methods. In Study II we evaluated robustness of cohort population model using dexamethasone maternal and fetal plasma concentrations obtained at childbirth after intramuscular injection of two 8 mg antenatal doses of dexamethasone phosphate in pregnant women. We implemented in NONMEM 7.6 the 3-cohort population as a mixture population model and applied first order conditional estimation, stochastic approximation, and importance sampling methods for parameter estimation. We showed that cohort estimation can quantify the variability in (log)normal populations where between-cohort variability is a substitute for between-subject variability. The cohort estimates of structural model parameters were equally accurate than the standard estimates and the accuracy and precision of estimates of inter-individual variability parameters for sparse data were better than for the standard maximum likelihood methods. Finally, we showed that the cohort population estimates provided meaningful quantification of one compartment model parameters for dexamethasone in parturient women where data were limited only to one blood sample per subject drawn after childbirth.
- Open Access
- 16 June 2025
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 14 (7) , 1133-1155
Tutorial for Modeling Delays in Biological Systems in the NONMEM Software
Delays in biological systems are a common phenomenon. The models for delays require specialized mathematical and numerical techniques such as transit compartments, delay differential equations (DDEs), and distributed DDEs (DDDEs). Because of mathematical complexity, DDEs and particularly DDDEs are infrequently used for modeling. DDEs are supported by most pharmacometric programs. Recently, DDDEs have been implemented in NONMEM that greatly improve the applicability of this technique in pharmacokinetic and pharmacodynamic (PKPD) modeling. The objective of this tutorial is to provide examples of PKPD models with delays and demonstrate how to implement them in NONMEM. All examples provide a brief description of the biology and pharmacology underlying model equations, explain how they are coded in the NONMEM control stream, and discuss results of data analysis models were used for. NONMEM codes for all models are presented in supporting information (Data S1). The tutorial concludes with a discussion of the pros and cons of presented delay modeling techniques with guidelines for which one might be preferred given the nature of the delay, available data, and the task to be performed.
- 16 June 2025
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 14 (7) , 1133-1155
Open AccessTutorial for Modeling Delays in Biological Systems in the NONMEM Software
Delays in biological systems are a common phenomenon. The models for delays require specialized mathematical and numerical techniques such as transit compartments, delay differential equations (DDEs), and distributed DDEs (DDDEs). Because of mathematical complexity, DDEs and particularly DDDEs are infrequently used for modeling. DDEs are supported by most pharmacometric programs. Recently, DDDEs have been implemented in NONMEM that greatly improve the applicability of this technique in pharmacokinetic and pharmacodynamic (PKPD) modeling. The objective of this tutorial is to provide examples of PKPD models with delays and demonstrate how to implement them in NONMEM. All examples provide a brief description of the biology and pharmacology underlying model equations, explain how they are coded in the NONMEM control stream, and discuss results of data analysis models were used for. NONMEM codes for all models are presented in supporting information (Data S1). The tutorial concludes with a discussion of the pros and cons of presented delay modeling techniques with guidelines for which one might be preferred given the nature of the delay, available data, and the task to be performed.
- Open Access
- 5 December 2023
- Published by Springer Nature in The AAPS Journal
- Vol. 26 (1) , 1-11
A Population Model of Time-Dependent Changes in Serum Creatinine in (Near)term Neonates with Hypoxic-Ischemic Encephalopathy During and After Therapeutic Hypothermia
The objective was to apply a population model to describe the time course and variability of serum creatinine (sCr) in (near)term neonates with moderate to severe encephalopathy during and after therapeutic hypothermia (TH). The data consisted of sCr observations up to 10 days of postnatal age in neonates who underwent TH during the first 3 days after birth. Available covariates were birth weight (BWT), gestational age (GA), survival, and acute kidney injury (AKI). A previously published population model of sCr kinetics in neonates served as the base model. This model predicted not only sCr but also the glomerular filtration rate normalized by its value at birth (GFR/GFR0). The model was used to compare the TH neonates with a reference full term non-asphyxiated population of neonates. The estimates of the model parameters had good precision and showed high between subject variability. AKI influenced most of the estimated parameters denoting a strong impact on sCr kinetics and GFR. BWT and GA were not significant covariates. TH transiently increased $$\mathrm{sCr}$$ in TH neonates over the first days compared to the reference group. Asphyxia impacted not only GFR, but also the $$\mathrm{sCr}$$ synthesis rate. We also observed that AKI neonates exhibit a delayed onset of postnatal GFR increase and have a higher $$\mathrm{sCr}$$ synthesis rate compared to no-AKI patients. Our findings show that the use of $$\mathrm{sCr}$$ as marker of renal function in asphyxiated neonates treated with TH to guide dose selection for renally cleared drugs is challenging, while we captured the postnatal sCr patterns in this specific population. Graphical Abstract- 5 December 2023
- Published by Springer Nature in The AAPS Journal
- Vol. 26 (1) , 1-11
Open AccessA Population Model of Time-Dependent Changes in Serum Creatinine in (Near)term Neonates with Hypoxic-Ischemic Encephalopathy During and After Therapeutic Hypothermia
The objective was to apply a population model to describe the time course and variability of serum creatinine (sCr) in (near)term neonates with moderate to severe encephalopathy during and after therapeutic hypothermia (TH). The data consisted of sCr observations up to 10 days of postnatal age in neonates who underwent TH during the first 3 days after birth. Available covariates were birth weight (BWT), gestational age (GA), survival, and acute kidney injury (AKI). A previously published population model of sCr kinetics in neonates served as the base model. This model predicted not only sCr but also the glomerular filtration rate normalized by its value at birth (GFR/GFR0). The model was used to compare the TH neonates with a reference full term non-asphyxiated population of neonates. The estimates of the model parameters had good precision and showed high between subject variability. AKI influenced most of the estimated parameters denoting a strong impact on sCr kinetics and GFR. BWT and GA were not significant covariates. TH transiently increased $$\mathrm{sCr}$$ in TH neonates over the first days compared to the reference group. Asphyxia impacted not only GFR, but also the $$\mathrm{sCr}$$ synthesis rate. We also observed that AKI neonates exhibit a delayed onset of postnatal GFR increase and have a higher $$\mathrm{sCr}$$ synthesis rate compared to no-AKI patients. Our findings show that the use of $$\mathrm{sCr}$$ as marker of renal function in asphyxiated neonates treated with TH to guide dose selection for renally cleared drugs is challenging, while we captured the postnatal sCr patterns in this specific population. Graphical Abstract - 4 November 2023
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 113 (1) , 257-267
Pharmacodynamic Age Structured Population Model For Cell Trafficking
- 4 November 2023
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 113 (1) , 257-267
Pharmacodynamic Age Structured Population Model For Cell Trafficking
- Open Access
- 14 March 2023
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 12 (5) , 668-680
Minimal physiologically‐based hybrid model of pharmacokinetics in pregnant women: Application to antenatal corticosteroids
Minimal physiologically‐based pharmacokinetic (mPBPK) models are an alternative to full physiologically‐based pharmacokinetic (PBPK) models as they offer reduced complexity while maintaining the physiological interpretation of key model components. Full PBPK models have been developed for pregnancy, but a mPBPK model eases the ability to perform a “top‐down” meta‐analysis melding all available pharmacokinetic (PK) data in the mother and fetus. Our hybrid mPBPK model consists of mPBPK models for the mother and fetus with connection by the placenta. This model was applied to describe the rich PK data of antenatal corticosteroid betamethasone (BET) jointly with the limited data for dexamethasone (DEX) in the mother and fetus. Physiologic model parameters were obtained from the literature while drug‐dependent parameters were estimated by the simultaneous fitting of all available data for DEX and BET. Maternal clearances of DEX and BET confirmed the literature values, and the expected fetal‐to‐maternal plasma ratios ranged from 0.3 to 0.4 for both drugs. Simulations of maternal plasma concentrations for the dosing regimens of BET and DEX recommended by the World Health Organization based on our findings revealed up to 60% lower exposures than found in nonpregnant women and offers a means of devising alternative dosing regimens. Our hybrid mPBPK model and meta‐analysis approach could facilitate assessment of other classes of drugs indicated for the treatment of pregnant women.
- 14 March 2023
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 12 (5) , 668-680
Open AccessMinimal physiologically‐based hybrid model of pharmacokinetics in pregnant women: Application to antenatal corticosteroids
Minimal physiologically‐based pharmacokinetic (mPBPK) models are an alternative to full physiologically‐based pharmacokinetic (PBPK) models as they offer reduced complexity while maintaining the physiological interpretation of key model components. Full PBPK models have been developed for pregnancy, but a mPBPK model eases the ability to perform a “top‐down” meta‐analysis melding all available pharmacokinetic (PK) data in the mother and fetus. Our hybrid mPBPK model consists of mPBPK models for the mother and fetus with connection by the placenta. This model was applied to describe the rich PK data of antenatal corticosteroid betamethasone (BET) jointly with the limited data for dexamethasone (DEX) in the mother and fetus. Physiologic model parameters were obtained from the literature while drug‐dependent parameters were estimated by the simultaneous fitting of all available data for DEX and BET. Maternal clearances of DEX and BET confirmed the literature values, and the expected fetal‐to‐maternal plasma ratios ranged from 0.3 to 0.4 for both drugs. Simulations of maternal plasma concentrations for the dosing regimens of BET and DEX recommended by the World Health Organization based on our findings revealed up to 60% lower exposures than found in nonpregnant women and offers a means of devising alternative dosing regimens. Our hybrid mPBPK model and meta‐analysis approach could facilitate assessment of other classes of drugs indicated for the treatment of pregnant women.
- Open Access
- 19 January 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (2) , 344
Scaling Pharmacodynamics from Rats to Humans to Support Erythropoietin and Romiplostim Combination Therapy to Treat Erythropoietin-Resistant Anemia
Recombinant human erythropoietin (rHuEPO) is one of the most effective drugs for the treatment of anemia in patients with chronic kidney disease. However, EPO-resistance is an important contributor to the increased risk of adverse effects. We previously showed that EPO treatment could induce precursor cell depletion, resulting in EPO-resistance. We further found that the combination of EPO with romiplostim, a thrombopoietin receptor agonist that can stimulate the expansion of hematopoietic stem cells, can treat EPO-resistance. In this study, we performed interspecies pharmacodynamic (PD) scaling of this combination therapy for human dose prediction. The pharmacokinetic parameters of both rHuEPO and romiplostim in humans were obtained from previous studies. The PD parameters obtained in rats were scaled to humans using allometric equations. The relationship between PD parameters of the megakaryocyte lineage from rats, monkeys, and humans was in agreement with those from the literature on allometric scaling. The PD response was translated to humans based on allometric scaling and agreed with the observed data. These parameters were used to simulate hemoglobin and platelet response in humans. RHuEPO 50 IU/kg thrice weekly and romiplostim 1 μg/kg once every 4 weeks from the second week is the recommended combination dosing regimen according to the model prediction. Our work successfully scaled the PD of rHuEPO and romiplostim monotherapy from rats to humans. The predicted dosing regimen of each drug in the combination therapy is less intensive than the approved starting dose of each drug, which supports additional evaluations of the combination therapy in humans.
- 19 January 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (2) , 344
Open AccessScaling Pharmacodynamics from Rats to Humans to Support Erythropoietin and Romiplostim Combination Therapy to Treat Erythropoietin-Resistant Anemia
Recombinant human erythropoietin (rHuEPO) is one of the most effective drugs for the treatment of anemia in patients with chronic kidney disease. However, EPO-resistance is an important contributor to the increased risk of adverse effects. We previously showed that EPO treatment could induce precursor cell depletion, resulting in EPO-resistance. We further found that the combination of EPO with romiplostim, a thrombopoietin receptor agonist that can stimulate the expansion of hematopoietic stem cells, can treat EPO-resistance. In this study, we performed interspecies pharmacodynamic (PD) scaling of this combination therapy for human dose prediction. The pharmacokinetic parameters of both rHuEPO and romiplostim in humans were obtained from previous studies. The PD parameters obtained in rats were scaled to humans using allometric equations. The relationship between PD parameters of the megakaryocyte lineage from rats, monkeys, and humans was in agreement with those from the literature on allometric scaling. The PD response was translated to humans based on allometric scaling and agreed with the observed data. These parameters were used to simulate hemoglobin and platelet response in humans. RHuEPO 50 IU/kg thrice weekly and romiplostim 1 μg/kg once every 4 weeks from the second week is the recommended combination dosing regimen according to the model prediction. Our work successfully scaled the PD of rHuEPO and romiplostim monotherapy from rats to humans. The predicted dosing regimen of each drug in the combination therapy is less intensive than the approved starting dose of each drug, which supports additional evaluations of the combination therapy in humans.
- Open Access
- 16 November 2022
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 12 (1) , 110-121
Developmental pharmacokinetics of indomethacin in preterm neonates: Severely decreased drug clearance in the first week of life
Indomethacin is used commonly in preterm neonates for the prevention of intracranial hemorrhage and closure of an abnormally open cardiac vessel. Due to biomedical advances, the infants who receive this drug in the neonatal intensive care unit setting have become younger, smaller, and less mature (more preterm) at the time of treatment. To develop a pharmacokinetics (PK) model to aid future dosing, we designed a prospective cohort study to characterize indomethacin PK in a dynamically changing patient population. A population PK base model was created using NONMEM, and a covariate model was developed in a primary development cohort and subsequently was tested for accuracy in a validation cohort. Postnatal age was a significant covariate for hepatic clearance (CLH) and renal clearance (CLR). The typical value of the total clearance (CL, the sum of CLR and CLH) was 3.09 ml/h and expressed as CL/WTmedian = 3.96 ml/h/kg, where WTmedian is the median body weight. The intersubject variability of CLR and CLH were 61% and 207%, respectively. The typical value of the volume of distribution Vp = 366 ml (Vp/WTmedian = 470 ml/kg), and its intersubject variability was 38.8%. Half‐life was 82.1 h. Compared with more mature and older preterm populations studied previously, indomethacin CL is considerably lower in this contemporary population. Model‐informed precision dosing incorporating important covariates other than weight alone offers an opportunity to individualize dosing in a susceptible patient undergoing rapid change.
- 16 November 2022
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 12 (1) , 110-121
Open AccessDevelopmental pharmacokinetics of indomethacin in preterm neonates: Severely decreased drug clearance in the first week of life
Indomethacin is used commonly in preterm neonates for the prevention of intracranial hemorrhage and closure of an abnormally open cardiac vessel. Due to biomedical advances, the infants who receive this drug in the neonatal intensive care unit setting have become younger, smaller, and less mature (more preterm) at the time of treatment. To develop a pharmacokinetics (PK) model to aid future dosing, we designed a prospective cohort study to characterize indomethacin PK in a dynamically changing patient population. A population PK base model was created using NONMEM, and a covariate model was developed in a primary development cohort and subsequently was tested for accuracy in a validation cohort. Postnatal age was a significant covariate for hepatic clearance (CLH) and renal clearance (CLR). The typical value of the total clearance (CL, the sum of CLR and CLH) was 3.09 ml/h and expressed as CL/WTmedian = 3.96 ml/h/kg, where WTmedian is the median body weight. The intersubject variability of CLR and CLH were 61% and 207%, respectively. The typical value of the volume of distribution Vp = 366 ml (Vp/WTmedian = 470 ml/kg), and its intersubject variability was 38.8%. Half‐life was 82.1 h. Compared with more mature and older preterm populations studied previously, indomethacin CL is considerably lower in this contemporary population. Model‐informed precision dosing incorporating important covariates other than weight alone offers an opportunity to individualize dosing in a susceptible patient undergoing rapid change.
- Open Access
- 23 July 2021
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 10 (8) , 826-838
Multiscale model of hepatitis C virus dynamics in plasma and liver following combination therapy
This work explores the application of a physiologically structured population (PSP) framework in modeling hepatitis C virus (HCV) kinetics. To do so, a model was developed for the viral RNA load in plasma and liver as observed in 15 patients treated with a combination therapy of pegylated interferon, ribavirin, and telaprevir. By including both intracellular and extracellular processes of the HCV lifecycle, the model provided a description of the treatment effect on the intracellular HCV lifecycle. Combining PSP models with a nonlinear mixed effects approach in a single model permits a natural inclusion of the direct‐acting antiviral effect on intracellular processes, which can then be integrated with the viral kinetics within the host while accounting for the interindividual variability between patients. This should allow an exploration of the treatment effect within the entire chronic HCV‐infected population.
- 23 July 2021
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 10 (8) , 826-838
Open AccessMultiscale model of hepatitis C virus dynamics in plasma and liver following combination therapy
This work explores the application of a physiologically structured population (PSP) framework in modeling hepatitis C virus (HCV) kinetics. To do so, a model was developed for the viral RNA load in plasma and liver as observed in 15 patients treated with a combination therapy of pegylated interferon, ribavirin, and telaprevir. By including both intracellular and extracellular processes of the HCV lifecycle, the model provided a description of the treatment effect on the intracellular HCV lifecycle. Combining PSP models with a nonlinear mixed effects approach in a single model permits a natural inclusion of the direct‐acting antiviral effect on intracellular processes, which can then be integrated with the viral kinetics within the host while accounting for the interindividual variability between patients. This should allow an exploration of the treatment effect within the entire chronic HCV‐infected population.
- 23 July 2021
- Published by Springer Nature in Journal of Pharmacokinetics and Pharmacodynamics
- Vol. 48 (6) , 763-802
Delay differential equations based models in NONMEM
Delay differential equations (DDEs) are commonly used in pharmacometric models to describe delays present in pharmacokinetic and pharmacodynamic data analysis. Several DDE solvers have been implemented in NONMEM 7.5 for the first time. Two of them are based on algorithms already applied elsewhere, while others are extensions of existing ordinary differential equations (ODEs) solvers. The purpose of this tutorial is to introduce basic concepts underlying DDE based models and to show how they can be developed using NONMEM. The examples include previously published DDE models such as logistic growth, tumor growth inhibition, indirect response with precursor pool, rheumatoid arthritis, and erythropoiesis-stimulating agents. We evaluated the accuracy of NONMEM DDE solvers, their ability to handle stiff problems, and their performance in parameter estimation using both first-order conditional estimation (FOCE) and the expectation–maximization (EM) method. NONMEM control streams and excerpts from datasets are provided for all discussed examples. All DDE solvers provide accurate and precise solutions with the number of significant digits controlled by the error tolerance parameters. For estimation of population parameters, the EM method is more stable than FOCE regardless of the DDE solver.
- 23 July 2021
- Published by Springer Nature in Journal of Pharmacokinetics and Pharmacodynamics
- Vol. 48 (6) , 763-802
Delay differential equations based models in NONMEM
Delay differential equations (DDEs) are commonly used in pharmacometric models to describe delays present in pharmacokinetic and pharmacodynamic data analysis. Several DDE solvers have been implemented in NONMEM 7.5 for the first time. Two of them are based on algorithms already applied elsewhere, while others are extensions of existing ordinary differential equations (ODEs) solvers. The purpose of this tutorial is to introduce basic concepts underlying DDE based models and to show how they can be developed using NONMEM. The examples include previously published DDE models such as logistic growth, tumor growth inhibition, indirect response with precursor pool, rheumatoid arthritis, and erythropoiesis-stimulating agents. We evaluated the accuracy of NONMEM DDE solvers, their ability to handle stiff problems, and their performance in parameter estimation using both first-order conditional estimation (FOCE) and the expectation–maximization (EM) method. NONMEM control streams and excerpts from datasets are provided for all discussed examples. All DDE solvers provide accurate and precise solutions with the number of significant digits controlled by the error tolerance parameters. For estimation of population parameters, the EM method is more stable than FOCE regardless of the DDE solver.
- 17 June 2021
- Published by Springer Nature in The AAPS Journal
- Vol. 23 (4) , 1-11
Population Model of Serum Creatinine as Time-Dependent Covariate in Neonates
Serum creatinine (sCr) is a commonly measured biomarker to estimate glomerular filtration rate (GFR) and therefore widely used as a covariate in population
- 17 June 2021
- Published by Springer Nature in The AAPS Journal
- Vol. 23 (4) , 1-11
Population Model of Serum Creatinine as Time-Dependent Covariate in Neonates
Serum creatinine (sCr) is a commonly measured biomarker to estimate glomerular filtration rate (GFR) and therefore widely used as a covariate in population